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ABSTRACT (204 words) 29 
Commercially available targeted panels miss genomic regions frequently altered in hepatocellular 30 
carcinoma (HCC). We sought to design and benchmark a sequencing assay for genomic screening 31 
in HCC. We designed an AmpliSeq custom panel targeting all exons of 33 protein-coding and 2 long 32 
non-coding RNA genes frequently mutated in HCC, TERT promoter, and 9 genes with frequent 33 
copy number alterations (CNA). Using this panel, the profiling of DNA from fresh-frozen (n=10, 34 
1495x) and/or formalin-fixed paraffin-embedded (FFPE) tumors with low-input DNA (n=36, 530x) 35 
from 39 HCCs identified at least one somatic mutation in 90% of the cases. Median of 2.5 (0-74) 36 
and 3 (0-76) mutations were identified in fresh-frozen and FFPE tumors, respectively. Benchmarked 37 
against the mutations identified from Illumina whole-exome sequencing (WES) of the corresponding 38 
fresh-frozen tumors (105x), 98% (61/62) and 100% (104/104) of the mutations from WES were 39 
detected in the 10 fresh-frozen tumors and the 36 FFPE tumors, respectively, using the HCC panel. 40 
Additionally, we identified 18 and 70 somatic mutations in coding and non-coding genes, 41 
respectively, not found by WES using our HCC panel. CNAs between WES and our HCC panel 42 
showed an overall concordance of 86%. In conclusion, we established a cost-effective assay for the 43 
detection of genomic alterations in HCC. 44 
 45 
Keywords: Hepatocellular carcinoma; somatic mutation; copy number alteration; targeted 46 
sequencing. 47 
 48 
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INTRODUCTION 50 
Sequencing technologies have allowed the discovery of genetic alterations essential in the 51 
diagnosis and treatment of human cancer or approval of new targeted therapies.1 Additionally, the 52 
presence of subclonal mutations has direct implications in the development of drug resistance.2, 3 In 53 
the era of precision medicine, the development of rapid, accurate, high-throughput and cost-54 
effective genomic assays to accommodate the increasingly genotype-based therapeutic approaches 55 
is required.4, 5 Currently, the costs of whole-genome and whole-exome sequencing (WES) are still 56 
prohibitive in the clinical setting, especially for small institutions. Furthermore, while DNA from fresh-57 
frozen tissue is ideal for genomic screening, it is not part of routine diagnostic practice at most 58 
hospitals and institutions. Instead, DNA from formalin-fixed paraffin-embedded (FFPE) material is 59 
frequently the only option. Moreover, DNA from small tumors, after reserving materials for 60 
histopathologic analyses, may be extremely limited. For research institutes, being able to exploit 61 
and re-visit archival materials associated with long-term follow-up but whose DNA may potentially 62 
be degraded is also highly desirable. Given these limitations, PCR-based sequencing panels may 63 
be more broadly applicable than capture-based solutions. 64 
 65 
Existing commercial sequencing panels, such as the amplicon-based Ion Torrent Oncomine 66 
Comprehensive Assayâ v3 (Thermo Fisher Scientific, MA, USA) and the capture-based Foundation 67 
Medicine FoundationOne assay, are broadly applicable to common cancer types. Compared to 68 
other common cancer types, however, hepatocellular carcinoma (HCC) has a distinct mutational 69 
profile. While HCC driver genes TP53 and CTNNB1 are also frequently mutated in cancers such as 70 
those of the lungs, the breasts and colon,6 genes such as APOB, ALB, HNF1A, HNF4A are 71 
significantly mutated only in HCC.7-17 The distinct mutational landscape of HCC is likely a result of 72 
the unique biology of hepatocyte differentiation and liver functions. Importantly, the frequently 73 
altered APOB, ALB and HNF4A are not targeted by most commercial assays. In the non-coding 74 
regions, recent commercially available panels include TERT promoter mutation hotspot (c.-75 
124C>T). However, long non-coding RNA (lncRNA) genes frequently mutated in HCC, such 76 
MALAT1 and NEAT1,16 have yet to be included in commercial panels or in exome capture panels. 77 
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Recent whole-genome studies have also uncovered mutation clusters in promoter regions of genes 78 
such as MED16, WDR74 and TFPI216, 18 that are not covered in commercial panels. 79 
 80 
In this study, we designed a high-throughput and cost-effective amplicon-based sequencing panel 81 
specifically to screen for somatic mutations and copy number alterations (CNAs) in HCC. Our panel 82 
includes genes and regions frequently altered in HCC, including those not currently covered by 83 
commercial panels. We tested the sequencing panel using fresh-frozen and FFPE materials with 84 
low-input DNA to evaluate the feasibility of this panel in routine diagnostics. 85 
 86 
MATERIALS AND METHODS 87 
Targeted panel design and generation 88 
A custom targeted sequencing panel focusing on the most frequently altered genes in HCC7-18 was 89 
designed using Ion Ampliseq Designer (Thermo Fisher Scientific). The panel (hereafter the “HCC 90 
panel”) covers all exons of 33 protein-coding genes, recurrently mutated lncRNA genes MALAT1 91 
and NEAT1 and the recurrently mutated promoter regions of TERT, WDR74, MED16 and TFPI2 92 
(Figure 1A and Supplementary Table S1).7-18 Nine genes frequently altered by copy number 93 
alterations (CNAs) as well as mutation hotspots in seven cancer genes are also covered (Figure 1A 94 
and Supplementary Table S1).7-18 The HCC panel was designed using the FFPE option for smaller 95 
amplicon size. The nine genes for CNA profiling were designed to be covered by at least 10 non-96 
overlapping amplicons evenly distributed across the length of the genes. The designed panel was 97 
further inspected by the white glove service (Thermo Fisher Scientific) for primer specificity in a 98 
multiplex PCR reaction. The HCC panel consists of 2120 amplicons split into two primer pools and 99 
covers genomic regions of ~203kb. 100 
 101 
Tissue samples 102 
Human tissues were obtained from patients undergoing diagnostic liver biopsy at the University 103 
Hospital Basel, Basel, Switzerland. Written informed consent was obtained from all included 104 
patients. Ultrasound-guided needle biopsies were obtained from tumor lesion(s) and adjacent non-105 
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tumoral liver tissue (Figure 1B). The study was approved by the Ethics committee of the north-106 
western part of Switzerland (Protocol Number EKNZ 2014-099). For all patients except cases 2, 6, 7 107 
and 9, a single tumor biopsy was included (Supplementary Table S2). For cases 6 and 7, two tumor 108 
biopsies were included, and for cases 2 and 9, three tumor biopsies were included. A portion of 109 
each biopsy was formalin-fixed paraffin-embedded for clinical purposes and the remaining portion of 110 
each biopsy was snap-frozen and stored at -80° for research purposes. For this study, 45 fresh-111 
frozen tumor biopsies and 39 fresh-frozen non-tumor biopsies from 39 patients were included. FFPE 112 
tissue samples that remained after diagnostic routine (36 tumor biopsies and 31 non-tumor biopsies 113 
from 36 patients) were included. Pathologic assessment of tumor content was performed by two 114 
expert hepatopathologists (M.S.M. and L.M.T.) using diagnostic hematoxylin-and-eosin slides.  115 
 116 
DNA extraction 117 
DNA from fresh-frozen biopsies was extracted using the ZR-Duet DNA/RNA MiniPrep Plus kit 118 
(Zymo Research, CA, USA) following the manufacturer’s instructions. Prior to extraction, tissue 119 
samples were crushed in liquid nitrogen to facilitate lysis. For DNA extraction from FFPE samples, 120 
one 5µm-thick slide was cut directly in the tube and DNA extracted with the DNeasy Blood and 121 
Tissue Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions as previously 122 
described.19, 20 DNA was quantified using the Qubit Fluorometer (Thermo Fisher Scientific). 123 
 124 
Library preparation and deep sequencing using the HCC panel 125 
Library preparation for the HCC panel was performed using the Ion AmpliSeq library kit 2.0 (Thermo 126 
Fisher Scientific) according to the manufacturer’s guidelines. For cases 2, 6, 7, and 9, DNA 127 
extracted from multiple fresh-frozen tumor biopsies was pooled equimolar prior to library preparation 128 
(Supplementary Table S2). In total, 20 fresh-frozen samples (10 tumor samples and 10 non-tumoral 129 
counterparts) and 67 FFPE samples (36 tumor biopsies and 31 non-tumoral counterparts) were 130 
sequenced using the HCC panel.  131 
 132 
The HCC panel consists of two pools of amplification primers. 10ng of DNA per sample was used 133 
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for library preparation for each pool. Amplification was performed according to the manufacturer’s 134 
guidelines. The amplicons from the two pools were combined and treated to digest the primers and 135 
to phosphorylate the amplicons. The amplicons were then ligated to Ion Adapters (Thermo Fisher 136 
Scientific) using DNA ligase. Finally, cleaning and purification of the generated libraries were 137 
performed with Agencourt AMPure XP (Beckman Coulter, CA, USA) according to the 138 
manufacturer’s guidelines. Quantification and quality control were performed with Ion Library 139 
TaqMan Quantitation Kit (Thermo Fisher Scientific). Samples were diluted to reach the 140 
concentration of 40pmol and then were pooled for sequencing. 25µl of the pooled libraries was 141 
loaded on Ion 530 Chip (Thermo Fisher Scientific) and processed in Ion Chef Instrument (Thermo 142 
Fisher Scientific). Sequencing was performed on Ion S5 XL system (Thermo Fisher Scientific).  143 
 144 
Sequence data analysis for the HCC panel  145 
Sequence reads were aligned to the human reference genome hg19 using TMAP within the Torrent 146 
Suite Software (v5.4) for the Ion S5XL system. Coverage analysis was performed using Picard’s 147 
CollectTargetedPcrMetrics tool (http://broadinstitute.github.io/picard/, v2.4.1, Supplementary Table 148 
S3). Uniformity of sequencing was defined as the proportion of target bases covered at >20% of 149 
mean amplicon coverage for a given sample. Comparison of the coverage for the two primer pools 150 
was performed using paired Wilcoxon test.  151 
 152 
Somatic mutations were identified using Torrent Variant Caller (v5.0.3, Thermo Fisher Scientific). 153 
For fresh-frozen samples, the corresponding fresh-frozen non-tumoral samples were used as the 154 
germline control. For FFPE samples, FFPE non-tumoral samples were used as the matched 155 
germline sample where available. Where FFPE non-tumoral samples were not available, the 156 
corresponding fresh-frozen non-tumoral samples were used as germline control. Mutations at 157 
hotspot residues were white-listed.21, 22 We filtered out mutations supported by <8 reads, and/or 158 
those covered by <10 reads in the tumor or <10 reads in the matched non-tumoral counterpart. Only 159 
those for which the tumor variant allele fraction (VAF) was >10 times that of the matched non-160 
tumoral VAF were retained to ensure the somatic nature of the variants. Due to the repetitive nature 161 
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and the high GC content of the TERT promoter region, TERT mutation hotspots (chr5:1295228 and 162 
chr5:1295250) were additionally screened. TERT promoter mutations were considered present if 163 
supported by at least 5 reads or variant allele fraction of at least 5%. All mutations were manually 164 
inspected using the Integrative Genomics Viewer (v2.3.69).23 165 
 166 
CNAs were defined as follows. For each sample, end-to-end sequence reads were extracted 167 
separately for the two amplicon pools. A copy number reference for each pool was generated using 168 
all non-tumoral samples to estimate overall read depth, log2 ratio and variability using the ‘reference’ 169 
function from CNVkit (v0.9.0).24 Amplicons with <100 read depth, absolute log2 ratio >1.5 or spread 170 
>1 were removed from copy number analysis. Protein-coding genes for which the complete coding 171 
region was included in the panel or for which amplicons were specifically designed for copy number 172 
analysis were included. Samples with excessive residual copy number log2 ratio (segment 173 
interquartile range >0.8) were excluded, as previously described.25 174 
 175 
For each tumor/non-tumor pairs, log2 ratio was computed for each amplicon, separately for the two 176 
amplicon pools using Varscan2 (v2.4.3).26 Log2 ratios for the two pools were separately centered 177 
then merged for segmentation using circular binary segmentation.27 CNAs were determined 178 
adopting a previously described approach.20 In brief, standard deviation (SD) of the log2 ratios of the 179 
40% of the central positions ordered by their log2 ratios was computed. Copy number gains and 180 
amplifications/ high gains were defined as +2SDs and +6SDs, respectively. Copy number losses 181 
and deep deletions were defined as -2.5SDs and -7SDs, respectively. All gene amplifications and 182 
deep deletions were visually inspected using log2 ratio plots. 183 
 184 
To evaluate the impact of tumor purity on CNA analysis, we performed an in silico simulation on 12 185 
cases (6 frozen and 6 FFPE, selected on the basis of the presence of gene amplification/ high gain 186 
or deep deletion), by replacing tumor reads with reads sampled from the normal samples to 187 
simulate tumor content 5%, 10%, 20% up to the actual tumor content for the samples. CNA analysis 188 
was performed as described above. 189 
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 190 
Whole exome sequencing (WES) 191 
WES was performed for DNA extracted from the 45 tumor biopsies and 39 non-tumoral counterparts 192 
from the 39 patients (Supplementary Table S2). Whole exome capture was performed using the 193 
SureSelectXT Clinical Research Exome (Agilent, CA, USA) platform according to the 194 
manufacturer’s guidelines. Sequencing (2x101bp) was performed at the Genomics Facility of ETH 195 
Zurich Department of Biosystems Science and Engineering (Basel, Switzerland) using Illumina 196 
HiSeq 2500 (Illumina, CA, USA) according to the manufacturer’s guidelines. Sequence reads were 197 
aligned to the reference human genome GRCh37 using Burrows-Wheeler Aligner-MEM (v0.7.12).28 198 
Local realignment, duplicate removal and base quality adjustment were performed using the 199 
Genome Analysis Toolkit (v3.6)29 and Picard (http://broadinstitute.github.io/picard/, v2.4.1).  200 
 201 
For WES samples, sequence reads overlapping with the target regions of the HCC panel were 202 
extracted for further comparative analyses. Sequencing statistics were evaluated for the overlap of 203 
the target regions of the WES and the HCC panel. In addition, for cases 2, 6, 7, and 9, for which 204 
DNA from multiple fresh-frozen tumor biopsies was pooled prior to sequencing using the HCC 205 
panel, WES reads from the multiple biopsies were merged to facilitate downstream comparisons. 206 
For all four cases, the number of reads obtained from WES of individual biopsies was comparable 207 
(Supplementary Table S3).  208 
 209 
Somatic single nucleotide variants and small insertions and deletions were detected using MuTect 210 
(v1.1.4)30 and Strelka (v1.0.15)31, respectively. We filtered out single nucleotide variants, and small 211 
insertions and deletions outside of the target regions, those with variant allelic fraction of <1% 212 
and/or those supported by <3 reads. We only retained variants for which the tumor VAF was >5 213 
times that of the matched non-tumoral VAF. We further excluded variants identified in at least two of 214 
a panel of 123 non-tumoral liver tissue samples, including the 39 non-tumoral samples in the current 215 
study, captured and sequenced using the same protocols using the artifact detection mode of 216 
MuTect2 implemented in Genome Analysis Toolkit (v3.6).29 All indels were manually inspected 217 
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using the Integrative Genomics Viewer 23. Copy number analysis was performed using FACETS 218 
(v0.5.13),32 and genes targeted by amplifications or deep deletions defined using the same 219 
thresholds as above. 220 
 221 
Pairwise comparisons between mutations identified by whole exome sequencing, fresh 222 
frozen and formalin-fixed paraffin-embedded tissues 223 
Pairwise comparisons of the somatic mutations identified by WES and by the HCC panel were 224 
performed, according to the originating biopsies (Supplementary Table S2). Discordant variants 225 
were re-evaluated and interrogated for their presence by supplying Torrent Variant Caller (v5.0.3) 226 
with their positions as the ‘hotspot list’ (for Ion Torrent sequencing) or by Genome Analysis Toolkit 227 
(v3.6) Unified Genotyper using the GENOTYPE_GIVEN_ALLELES mode.  228 
 229 
Sanger sequencing 230 
To validate the discordant variants, Sanger sequencing was performed on both DNA from the fresh-231 
frozen and the corresponding FFPE tumor biopsies. PCR amplification of 5ng of genomic DNA was 232 
performed using the AmpliTaq 360 Master Mix Kit (Thermo Fisher Scientific) on a Veriti Thermal 233 
Cycler (Thermo Fisher Scientific) as previously described20 (Supplementary Table S4). PCR 234 
fragments were purified with ExoSAP-IT (Thermo Fisher Scientific). Sequencing reactions were 235 
performed on a 3500 Series Genetic Analyzer instrument using the ABI BigDye Terminator 236 
chemistry (v3.1, Thermo Fisher Scientific) according to manufacturer’s instructions. All analyses 237 
were performed in duplicate. Sequences of the forward and reverse strands were analyzed using 238 
MacVector software (MacVector, Inc, MA, USA).20 239 
 240 
Analysis of The Cancer Genome Atlas (TCGA) data 241 
To determine the frequencies of high-level copy number gains/ focal amplifications, and deep 242 
deletions/ focal homozygous deletions in HCC, we obtained the GISTIC 2.0 copy number calls for 243 
the TCGA HCC cohort from the cBioPortal.33 High-level gains and deep deletions were defined as 244 
those with GISTIC copy number state 2 and -2, respectively. Focal amplifications and focal 245 
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homozygous deletions were defined as high-level gains and deep deletions that affected <25% of a 246 
given chromosome arm. For the 37 genes included in the copy number analysis, we computed the 247 
frequencies of high-level gains/deep deletions and of focal amplifications/focal homozygous 248 
deletions. 249 
 250 
Statistical analysis 251 
Correlation analyses were performed using Pearson’s r and r2. Statistical analyses were performed 252 
in R (v3.4.2). 253 
 254 
RESULTS 255 
HCC-specific custom targeted sequencing panel design and quality assessment. 256 
We designed an HCC sequencing panel specifically targeting genes and genomic regions 257 
frequently altered in HCC7-18 (Figure 1A and Supplementary Table S1). The HCC panel consists of 258 
complete coding regions of 33 genes involved in several pathways implicated in HCC pathogenesis, 259 
including the WNT pathway (CTNNB1, AXIN1), chromatin remodelling (ARID1A, ARID2 and BAP1), 260 
cell cycle regulation (CDKN1A, CDKN2A, CDKN2B, CCND1, RPS6KA3, RB1 and TP53), 261 
inflammatory response (IL6R, IL6ST) and hepatocyte differentiation (ALB, APOB, HNF1A, HNF4A). 262 
Additionally, the HCC panel also targets recurrently mutated lncRNA genes MALAT1 and NEAT1 263 
and recurrently mutated promoter regions of TERT, WDR74, MED16 and TFPI2. Genes frequently 264 
altered by copy number alterations (CNAs, e.g. CCNE1, VEGFA, TERT), and mutation hotspots in 265 
BRAF, EEF1A1, HRAS, IL6ST, KRAS, NRAS and PIK3CA are also targeted. To enable the efficient 266 
profiling of DNA samples derived from potentially degraded FFPE materials, the panel was 267 
designed using the FFPE option for smaller amplicon size, with a mean amplicon size of 118bp 268 
(range 63bp-252bp, Figure 2A). We tested the HCC panel on the DNA extracted from 20 fresh-269 
frozen samples (10 from tumor biopsies and 10 from non-tumoral counterparts) and 67 FFPE 270 
samples (36 from tumor biopsies and 31 from non-tumoral counterparts) obtained from 39 patients 271 
(Figure 1B and Supplementary Table S2). 272 
 273 
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We first performed a coverage analysis of the HCC panel using the 10 fresh-frozen and 31 FFPE 274 
non-tumoral DNA samples. In the fresh-frozen and FFPE non-tumoral DNA samples, we achieved a 275 
mean coverage of 1478x (range 925x-2420x) and 580x (range 263x-1300x), respectively (Figure 2B 276 
and Supplementary Table S3). There was no difference between the depth of coverage of the two 277 
pools of amplicons (P=0.9879, paired Wilcoxon test, Supplementary Figure S1A). At least 96.8% 278 
and 91.1% of the amplicons were covered at >30x and at least 98.7% and 95.6% of the amplicons 279 
were covered at >10x in the fresh-frozen and FFPE non-tumor samples (Figure 2C and 280 
Supplementary Figure S1B). Median uniformity (defined as the proportion of target bases covered 281 
at >20% of the mean amplixcon coverage of a given sample) was 89.9% (range 86.8%-91.5%) in 282 
the fresh-frozen samples and 89.0% (range 73.3%-92.3%) in the FFPE samples (Figure 2D). As 283 
expected, depth of sequencing of the amplicons was associated with GC content, with reduced 284 
depth at extreme GC content (Figure 2E). 285 
 286 
HCC panel captured somatic mutations concordant with WES and identified additional 287 
mutations 288 
Next, we evaluated the somatic mutations identified using the 10 fresh-frozen tumor-non-tumoral 289 
pairs sequenced using the HCC panel. We achieved a median sequencing depth of 1495x (range 290 
1026x-1855x) in the tumor samples (Figure 2B, Supplementary Table S3). A median of 2.5 (range 291 
0-74) somatic mutations were identified, including a median of 2 (range 0-52) mutations in protein-292 
coding genes (Figure 3A and Supplementary Table S4). No somatic mutations were identified for 293 
2/10 cases (cases 3 and 12), although both cases had ≥50% tumor cell content (Supplementary 294 
Table S2). One case (case 9) exhibited a hypermutator phenotype with 74 somatic mutations 295 
identified.  296 
 297 
To evaluate the somatic mutations defined using the HCC panel, we used the somatic mutations 298 
derived from whole-exome sequencing (WES) using the orthogonal Illumina technology of the same 299 
DNA aliquots from the fresh-frozen tumors and matched non-tumor samples as our benchmark 300 
(Figure 1B). Considering only the coding regions covered by our HCC panel, the median depths of 301 
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WES was 114x (range 92x-345x) and 51x (range 45x-84x) in the fresh-frozen tumors and matched 302 
non-tumor samples, respectively (Supplementary Table S3). WES analysis confirmed that no 303 
mutations were present within the targeted protein coding regions in cases 3 and 12 and that case 9 304 
was hypermutated (Figure 3B). Of the 62 mutations in the coding region identified from WES 305 
analysis, 61 (98%) were also called by our HCC panel analysis (Figure 3B). One NRAS Q61K 306 
hotspot mutation (case 6) was missed using our HCC panel. Manual review of this position revealed 307 
that the mutation had variant allele fraction of 2.5% by WES and 2.0% by the HCC panel 308 
(Supplementary Figure S2 and Supplementary Table S4). It should, however, be noted that 2% is 309 
very close to the detection limit of the current sequencing technologies. 310 
 311 
Compared to the WES analysis, our HCC panel analysis revealed an additional six mutations in the 312 
coding regions, including five in case 9 and one in case 11 (Figure 3B). Manual review of the WES 313 
data revealed that all six mutations were in fact supported by at least one read in WES, but those 314 
positions were covered at reduced depth, with 4/6 covered by ≤40 reads (including 3 in LRP1B) and 315 
5/6 ≤80 reads (Supplementary Figure S2C and Supplementary Table S4). This suggests that the 316 
increased sensitivity in our HCC panel analysis is likely due to the increased depth achieved. 317 
 318 
Additional to the mutations in the protein coding regions, our HCC panel also targeted the lncRNA 319 
genes MALAT1 and NEAT1, as well as the promoter regions of TERT, WDR74, MED16 and TFPI2 320 
(Figure 1A). Within these non-coding regions, we identified an additional 32 mutations across the 10 321 
cases, representing a 48% gain of information compared to sequencing the protein coding genes 322 
alone (Figure 3B). TERT promoter mutations were found in 60% (6/10) of cases and 16 somatic 323 
mutations in the lncRNA gene NEAT1 were identified in 40% (4/10) of cases (Figure 3B and 324 
Supplementary Table S4).  325 
 326 
Taken together, for the protein coding genes frequently mutated in HCC, our HCC panel analysis 327 
produced highly reliable results compared to WES. Given the increased sequencing depth achieved 328 
using the HCC panel, we identified somatic mutations that were missed by WES. Importantly, our 329 
  13 
HCC panel analysis enabled us to identify somatic mutations in promoter regions and frequently 330 
mutated lncRNA genes. 331 
 332 
HCC panel analysis identified somatic mutations in FFPE diagnostic biopsies with low input 333 
DNA 334 
Nucleic acids from diagnostic specimens are frequently derived from small FFPE samples. 335 
Therefore, we sought to determine whether our HCC panel could also be used for somatic 336 
mutational screening using low-input DNA (20ng) extracted from FFPE samples. We subjected the 337 
DNA extracted from 36 diagnostic FFPE tumor biopsies to HCC panel sequencing to a median 338 
depth of 530x (range 192x-1257x, Figures 1A and 2B-C, Supplementary Table S3). The median 339 
tumor content for these 36 cases was 90% (range 5%-100%, Supplementary Table S2), thus 340 
representative of the distribution of tumor content in diagnostic samples in clinical practice. We 341 
identified a median of 3 mutations (range 0-76) per sample, including a median of 2 (range 0-53) 342 
mutations in the coding regions (Figure 4, Supplementary Figure S3 and Supplementary Table S4). 343 
No somatic mutations were identified for 8% (3/36) of cases (cases 7, 12 and 37), indicating that at 344 
least one somatic mutation could be detected in 92% of HCC diagnostic samples. Of note, while we 345 
were unable to detect somatic mutations in the one biopsy with 5% tumor content, we were able to 346 
detect somatic alterations in samples with 30%-40% tumor content. 347 
 348 
We compared the mutations identified in protein-coding genes from these 36 FFPE diagnostic 349 
biopsies to those identified by WES of the DNA from the corresponding fresh-frozen biopsies. All 350 
104 mutations identified from WES analysis were also called based on our HCC panel analysis 351 
(Figure 4 and Supplementary Figure S3), with 21/36 (58%) of our cases harboring CTNNB1 352 
mutations, a higher proportion than the TCGA and other HCC cohorts that is likely due to the higher 353 
percentage of alcohol-associated HCC (Supplementary Tables S1 and S2).15 Additionally, we 354 
identified 18 mutations in the coding regions that were not found in the WES analysis in 11 cases. 355 
Of these 18, 13 were evident in WES but were not identified as mutations in the WES analysis, 356 
predominantly due to low sequencing depth (Supplementary Figures S2D and S3). The remaining 357 
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five mutations were verified to be present in the corresponding FFPE samples but absent in the 358 
fresh-frozen samples by Sanger sequencing (Supplementary Figure S4 and Supplementary Table 359 
S4), indicating that they were genuine discordances between the fresh-frozen and FFPE DNA and 360 
not false positive calls from the HCC panel assay. Of note, 2/5 mutations validated to be absent 361 
from the fresh-frozen DNA affected mutation hotspots in CTNNB1 (p.Asp32Asn and p.Ser45Ala, 362 
Figure 4 and Supplementary Figure S4). The increased number of detected mutations by our HCC 363 
panel analysis was likely due to a combination of intra-tumor heterogeneity and the higher 364 
sequencing depth achieved.  365 
 366 
Considering the 36 FFPE diagnostic biopsies, our HCC panel identified 70 somatic mutations in 367 
lncRNA genes and promoter regions, including 22 TERT promoter mutations (Figure 4 and 368 
Supplementary Table S4). Somatic mutations in lncRNA genes and promoter regions accounted for 369 
37% of the total number of somatic mutations identified in the FFPE samples.  370 
 371 
Compared to the very high correlation of VAF between the sequencing platforms used in the fresh-372 
frozen samples (r=0.89, r2=0.79, Pearson correlation), the correlation between WES from fresh-373 
frozen samples and HCC panel using FFPE samples was more modest (r=0.67, r2=0.45, Pearson 374 
correlation, Supplementary Figure S2A-B). We observed that mutations with large deviations in 375 
VAFs between the sequencing platforms used in the fresh-frozen samples tended to be covered at 376 
reduced depths on either platform (Supplementary Figure S2C). Similar observations could be 377 
made between VAFs of exome (fresh-frozen) and HCC panel (FFPE, Supplementary Figure S2D). 378 
The deviations in the latter may be more noticeable by the overall lower depth achieved in the FFPE 379 
samples compared to the HCC panel sequencing of the fresh-frozen samples. Intra-tumor 380 
heterogeneity between the fresh-frozen and FFPE aliquots likely contributed to the reduced 381 
correlation. 382 
 383 
 384 
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Taken together these results suggest that our HCC panel analysis has high specificity and 385 
sensitivity in somatic mutation detection. Furthermore, somatic mutations in promoter regions 386 
(TERT promoter) and lncRNA genes (MALAT1 and NEAT1) highly mutated in HCC can also be 387 
detected. 388 
 389 
Copy number analysis of the HCC panel reveals high concordance with WES 390 
We sought to determine whether our HCC panel could also be used to detect CNAs. Of the genes 391 
targeted on the panel, we evaluated our ability to detect CNAs in 42 genes (complete coding 392 
regions covered and genes with amplicons tiled across the length of the genes for CNA detection, 393 
Figure 1A and Supplementary Table S1). Using the 41 non-tumoral samples, we assessed the 394 
variability of the depth of coverage in the amplicons targeting the 42 genes (Methods). After 395 
removing amplicons with low depth of coverage or high variability, 1,483 amplicons were used for 396 
CNA profiling. To assess our ability to evaluate per-gene CNA detection, we further paired each 397 
non-tumoral sample with two others randomly selected, gender-matched non-tumoral samples. We 398 
observed that the copy number log2 ratio of five genes, namely LRP1B, ALB, BRD7, ACVR2A and 399 
IRF2, was variable (SD>0.3) and therefore these genes were excluded from further CNA analyses. 400 
37 genes were included in the CNA analysis. 401 
 402 
We compared the copy number profiles of matched fresh-frozen tumor-non-tumor pairs and those 403 
derived from WES. Of the 10 fresh-frozen pairs sequenced using the HCC panel, one was excluded 404 
for excessive residual copy number log2 ratio (segment interquartile range >0.8).25 For the nine 405 
evaluable samples, we found a correlation of r=0.80 (r2=0.64) between the copy number log2 ratio of 406 
the two platforms (Figure 5A). When we compared the copy number profiles of the 34 evaluable 407 
FFPE tumors with the matched profiles from WES, we observed a correlation of r=0.73 (r2=0.54) 408 
between the copy number log2 ratios (Figure 5A). Overall, 86% of the evaluable genes had 409 
concordant copy number states (Figure 5B). 410 
 411 
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It has previously been reported that tumor purity had an impact on the ability to make CNA calls.25, 34 412 
We therefore evaluated the impact of tumor purity on CNA analysis using an in silico simulation on 413 
12 cases (6 fresh-frozen and 6 FFPE, selected on the basis of the presence of gene amplification/ 414 
high gain or deep deletion), by replacing tumor reads with reads sampled from the normal samples 415 
to simulate tumor content 5%, 10%, 20% up to the actual tumor content for the samples. We 416 
observed that amplifications/ high gains were readily detected at 5% tumor content in many cases 417 
and at 20% in all cases (Supplementary Figure S5). In our cohort, deep deletions could not be 418 
detected at tumor content <40%. 419 
 420 
Taken together, our results demonstrate that, despite profiling only a small number of genes, our 421 
HCC panel is able to detect CNAs in genes frequently gained or lost in HCC in both fresh-frozen 422 
and FFPE tumor samples with low input DNA. 423 
 424 
DISCUSSION 425 
HCC has a distinct mutational landscape compared to the major tumor entities. Numerous genes 426 
have been found to be mutated frequently in HCC but rarely in other tumors, such as those 427 
important for hepatocyte differentiation (ALB, APOB, HNF1A, HNF4A) and inflammatory response 428 
(IL6R, IL6ST). Given the relative rarity of HCC, these genes are currently not targeted or are only 429 
partially targeted in commercial panels (e.g. Oncomine Comprehensive Panel v3â) and in panels 430 
used by sequencing services (e.g. FoundationOne assay, Supplementary Table S1). Thus, the 431 
currently available commercial assays for genomic profiling have suboptimal utility for HCC and a 432 
targeted sequencing panel specifically designed for HCC is warranted.  433 
 434 
In this study, we designed a custom Ion Torrent AmpliSeq sequencing panel, targeting all exons of 435 
33 protein-coding genes, two lncRNA genes, promoter regions of four genes previously found to be 436 
recurrently mutated in HCC, nine genes frequently affected by copy number alterations (CNAs), and 437 
mutation hotspots in seven cancer genes.7-17 Importantly, a number of the genes targeted using our 438 
HCC panel are not currently on these two commercial panels. Of the 39 cases profiled with the HCC 439 
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panel (including both fresh-frozen and FFPE samples), we detected at least one somatic mutation in 440 
90% (35/39) of cases. Of the mutations in coding genes found using our panel, 22% (42/189) would 441 
have missed by both Oncomine Comprehensive Panel v3â and the FoundationOne assay. 442 
Additionally, recent whole-genome studies of HCC have revealed frequent mutations in lncRNA 443 
genes NEAT1 and MALAT1, both of which are not currently targeted by commercial panels. In fact, 444 
we found that around 1/3 of the mutations on the HCC panel were within the promoter and lncRNA 445 
regions. 446 
 447 
We benchmarked our mutation screening and copy number profiling results from the HCC panel 448 
against those obtained from whole-exome sequencing (WES) by the orthogonal Illumina 449 
sequencing technology. We demonstrated that all but one mutation identified from WES were 450 
detected using our HCC panel. We identified an additional 10-15% of mutations within the coding 451 
regions. The majority of these additional mutations were in fact supported by few reads by WES, 452 
thus our increased sensitivity was likely a direct result of the increased sequencing depth of both the 453 
tumor and the matched normal samples achieved. Crucially, however, we found evidence of intra-454 
tumor genetic heterogeneity between the adjacent fresh-frozen and FFPE biopsies, including two 455 
CTNNB1 mutations, suggesting that in these cases, the CTNNB1 mutations were not trunk 456 
mutations. 457 
 458 
While CNA detection using capture-based methods has been successful for targeted sequencing 459 
panel of several hundred genes,35 CNA detection using amplicon-based targeted sequencing has 460 
proven more difficult. A recent study investigated the use of an amplicon-based sequencing strategy 461 
targeting all exons of 113 genes related to DNA repair.25 The authors demonstrated that, with an 462 
appropriate analysis strategy and quality control, amplicon-based sequencing strategy is feasible 463 
and cost-effective for CNA profiling in FFPE samples.25 In the current study, the strategy of 464 
computing and centering the log2 ratios for the primer two pools separately, prior to merging and 465 
segmentation proved to be an effective strategy in resolving issues associated with variable 466 
amplification efficiencies, with 86% of the genes showing concordant copy number states. 467 
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Considering the few studies investigating the use of small targeted sequencing panel for CNA 468 
profiling, further benchmarking studies comparing analysis strategies and including larger sample 469 
size will likely improve the accuracies.  470 
 471 
In the clinical setting, the quality, type and amount of input materials for genomic profiling are crucial 472 
considerations, particularly in light of the smaller tumors being detected in screening programs. 473 
Here we demonstrated that the HCC panel could be used for genomic screening with high 474 
sensitivity and specificity with very low input DNA (20ng) derived from FFPE samples without 475 
compromising the results. Although based on an analysis of the TCGA HCC cases, 92% and 85% 476 
of the cases would have exhibited at least 1 non-synonymous mutation using the FoundationOne 477 
and the Oncomine assays, respectively, our HCC panel holds the advantage of much lower input 478 
requirement than that required for commercial panels (e.g. >40micron tissue samples for the 479 
FoundationOne assay) and for capture-based targeted sequencing strategies.35 We further 480 
demonstrated that somatic genetic alterations (somatic mutations and amplifications) could be 481 
detected from tumor samples with as low as 30% tumor content. Considering that we could not 482 
detect mutations in the one sample with 5% tumor content, we contend that 30% may be the lower 483 
limit of successful genomic profiling. Although lower limits (~20%) have also been reported,36 we did 484 
not have the samples to verify this. The samples included in this study are de facto samples 485 
obtained from routine diagnostic practice and we demonstrated that our low input DNA requirement 486 
facilitates genomic profiling from very small biopsies. 487 
 488 
Driver genetic alterations have not yet become a tangible tool in clinical decision making for the 489 
treatment of HCC, thus the immediate clinical application of our panel may be limited. However, 490 
recent studies have described the association of TERT promoter and CTNNB1 exon 3 mutations 491 
with increased risk of malignant transformation of hepatocellular adenomas,37, 38 more frequent 492 
HNF1A and IL6ST mutations in hepatocellular adenomas than HCCs,37 as well as TP53 mutation as 493 
a poor prognostic indicator in HCC.39-41 These associations suggest a potential utility of genomic 494 
profiling in prognostication for hepatocellular adenomas and HCCs, in tissues or in even in cell-free 495 
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DNA.41, 42 In terms of potential targetable alterations, three somatic mutations identified in our cohort 496 
of HCC are molecular targets in other cancer types according to OncoKB.43 These include ATM loss 497 
of function mutation using olaparib in prostate cancer (level 4; biological evidence), NRAS hotspot 498 
mutation with binimetinib or in combination with ribociclib in melanoma (level 3; clinical evidence) 499 
and TSC2 mutation with everolimus in central nervous system cancer (level 2; standard of care).43 500 
Application of our panel in clinical decision may become feasible in the future.  501 
 502 
This study has several limitations. Firstly, the targeted nature of our HCC panel means that copy 503 
number profiling is not genome-wide and is restricted to the genes included on the panel. Clinically, 504 
focal amplifications, compared to gains of chromosome arm, are more likely to be true driver genetic 505 
event and may be considered drug targets. The targeted nature of the HCC panel means it may be 506 
difficult to distinguish the two scenarios. However, a re-analysis of the TCGA data suggests that  507 
high-level gains of chr11q13.3 (encompassing CCND1, FGF19, FGF3, FGF4) are almost always 508 
focal amplifications (>93%), while 50-70% of high-level gains of TERT and VEGFA are focal 509 
amplifications (Supplementary Table S5). By contrast, high-level gains of chr1q (SETDB1 and IL6R) 510 
and chr8q (NCOA2, MYC and PTK2) are frequently non-focal (<10%), consistent with the frequent 511 
high-level gain of entire arms of chr1q and chr8q.44 For deletions, most deep deletions are focal 512 
deletions, including all deletions (100%) in ARID2, AXIN1, CDKN2A/B, PTEN and TSC1/2. These 513 
results suggest that for CNAs affecting some of the most promising drug targets on the HCC panel 514 
are frequently true focal CNAs. Secondly, given that we identified a median of 2-3 mutations per 515 
tumor, we would not be able to accurately define tumor mutational burden, a putative biomarker for 516 
response to immune therapy.45 Thirdly, the HCC panel does not include unique molecular 517 
identifiers, which would be useful to assess library complexity, particularly for samples with low input 518 
DNA. We envisage that the addition of unique molecular identifiers would be particularly beneficial 519 
for the study of cell-free DNA from HCC patients.41, 42 Fourthly, we designed the panel specific for 520 
HCC. Recent studies have revealed that mixed HCC/cholangiocarcinoma and cholangiocarcinoma 521 
have recurrent mutations in genes such as IDH1/2,46 while FRK mutations decrease in frequency 522 
from hepatocellular adenoma to HCC.37 These genes are not covered by the HCC panel. However, 523 
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as an amplicon-based sequencing panel, adding amplicons to include genes that may assist in the 524 
differential diagnosis of HCC is straightforward.  525 
 526 
In conclusion, our study demonstrated that our HCC panel is a cost-effective strategy for mutation 527 
screening and copy number profiling for routine diagnostic HCC samples with low input DNA.  528 
 529 
  530 
  21 
ACKNOWLEDGMENTS 531 
None  532 
 533 
AUTHOR’S CONTRIBUTION  534 
S.P., C.K.Y.N., and L.M.T. conceived and supervised the study; L.Q, M.S.M., S.P, C.K.Y.N. and 535 
L.M.T. performed literature search and designed the sequencing panel; S.W and M.H.H. provided 536 
the samples and the whole exome sequencing data; V.Pa., N.T., V.Pe., M.L. and S.P. performed 537 
DNA extraction, library preparation and sequencing; A.G. and C.K.Y.N. developed the bioinformatic 538 
pipeline for mutation calling; V.Pa., A.G., S.P., C.K.Y.N. and L.M.T. analysed the results and wrote 539 
the manuscript. 540 
 541 
 542 
  543 
  22 
REFERENCES 544 
 545 
1. Chin L, Andersen JN, Futreal PA: Cancer genomics: from discovery science to personalized 546 
medicine. Nat Med 2011, 17:297-303. 547 
2. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, 548 
Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, 549 
Ghiorghiu S, Papadimitrakopoulou VA, Investigators A: Osimertinib or Platinum-Pemetrexed 550 
in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017, 376:629-640. 551 
3. Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow 552 
C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, 553 
Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S: Activating ESR1 Mutations 554 
Differentially Affect the Efficacy of ER Antagonists. Cancer Discov 2017, 7:277-287. 555 
4. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba, II, Varella-Garcia M, 556 
Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, 557 
Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone 558 
G, Ladanyi M, Kugler K, Minna JD, Bunn PA: Using multiplexed assays of oncogenic drivers 559 
in lung cancers to select targeted drugs. JAMA 2014, 311:1998-2006. 560 
5. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZY, 561 
Won HH, Scott SN, Brannon AR, O'Reilly C, Sadowska J, Casanova J, Yannes A, 562 
Hechtman JF, Yao J, Song W, Ross DS, Oultache A, Dogan S, Borsu L, Hameed M, Nafa K, 563 
Arcila ME, Ladanyi M, Berger MF: Memorial Sloan Kettering-Integrated Mutation Profiling of 564 
Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation 565 
Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn 2015, 17:251-566 
264. 567 
  23 
6. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, 568 
Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, 569 
Wilson RK, Raphael BJ, Ding L: Mutational landscape and significance across 12 major 570 
cancer types. Nature 2013, 502:333-339. 571 
7. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-572 
Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, Laurent A, Couchy G, 573 
Letouze E, Calvo F, Zucman-Rossi J: Integrated analysis of somatic mutations and focal 574 
copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat 575 
Genet 2012, 44:694-698. 576 
8. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo 577 
M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, 578 
Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, 579 
Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, 580 
Yamamoto M, Yamada T, Chayama K, Kosuge T, et al.: Whole-genome sequencing of liver 581 
cancers identifies etiological influences on mutation patterns and recurrent mutations in 582 
chromatin regulators. Nat Genet 2012, 44:760-764. 583 
9. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, 584 
Lawrence MS, Parker JS, Li J, Powers S, Kim H, Fischer S, Guindi M, Ghanekar A, Chiang 585 
DY: Identification of driver genes in hepatocellular carcinoma by exome sequencing. 586 
Hepatology 2013, 58:1693-1702. 587 
10. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, 588 
Hauptschein R, Rejto PA, Fernandez J, Wang G, Zhang Q, Wang B, Chen R, Wang J, Lee 589 
NP, Zhou W, Lin Z, Peng Z, Yi K, Chen S, Li L, Fan X, Yang J, Ye R, Ju J, Wang K, Estrella 590 
H, Deng S, Wei P, Qiu M, Wulur IH, et al.: Whole-genome sequencing identifies recurrent 591 
mutations in hepatocellular carcinoma. Genome Res 2013, 23:1422-1433. 592 
  24 
11. Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM, Sung CO, Baek D, Haq F, Ansari AA, Lee SY, 593 
Chun SM, Choi S, Choi HJ, Kim J, Kim S, Hwang S, Lee YJ, Lee JE, Jung WR, Jang HY, 594 
Yang E, Sung WK, Lee NP, Mao M, Lee C, Zucman-Rossi J, Yu E, Lee HC, Kong G: 595 
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 596 
aberrations for patient stratification. Hepatology 2014, 60:1972-1982. 597 
12. Jhunjhunwala S, Jiang Z, Stawiski EW, Gnad F, Liu J, Mayba O, Du P, Diao J, Johnson S, 598 
Wong KF, Gao Z, Li Y, Wu TD, Kapadia SB, Modrusan Z, French DM, Luk JM, Seshagiri S, 599 
Zhang Z: Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol 600 
2014, 15:436. 601 
13. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, 602 
Slagle BL, Nakamura H, Yamamoto S, Shinbrot E, Hama N, Lehmkuhl M, Hosoda F, Arai Y, 603 
Walker K, Dahdouli M, Gotoh K, Nagae G, Gingras MC, Muzny DM, Ojima H, Shimada K, 604 
Midorikawa Y, Goss JA, Cotton R, Hayashi A, Shibahara J, Ishikawa S, Guiteau J, Tanaka 605 
M, Urushidate T, Ohashi S, Okada N, et al.: Trans-ancestry mutational landscape of 606 
hepatocellular carcinoma genomes. Nat Genet 2014, 46:1267-1273. 607 
14. Shiraishi Y, Fujimoto A, Furuta M, Tanaka H, Chiba K, Boroevich KA, Abe T, Kawakami Y, 608 
Ueno M, Gotoh K, Ariizumi S, Shibuya T, Nakano K, Sasaki A, Maejima K, Kitada R, Hayami 609 
S, Shigekawa Y, Marubashi S, Yamada T, Kubo M, Ishikawa O, Aikata H, Arihiro K, Ohdan 610 
H, Yamamoto M, Yamaue H, Chayama K, Tsunoda T, Miyano S, Nakagawa H: Integrated 611 
analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic 612 
aberrations driven by somatic genomic changes in liver cancers. PLoS One 2014, 613 
9:e114263. 614 
15. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, 615 
Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent 616 
A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, 617 
  25 
Llovet JM, Zucman-Rossi J: Exome sequencing of hepatocellular carcinomas identifies new 618 
mutational signatures and potential therapeutic targets. Nat Genet 2015, 47:505-511. 619 
16. Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, 620 
Kawakami Y, Ueno M, Gotoh K, Ariizumi S, Wardell CP, Hayami S, Nakamura T, Aikata H, 621 
Arihiro K, Boroevich KA, Abe T, Nakano K, Maejima K, Sasaki-Oku A, Ohsawa A, Shibuya 622 
T, Nakamura H, Hama N, Hosoda F, Arai Y, Ohashi S, Urushidate T, Nagae G, Yamamoto 623 
S, Ueda H, Tatsuno K, Ojima H, et al.: Whole-genome mutational landscape and 624 
characterization of noncoding and structural mutations in liver cancer. Nat Genet 2016, 625 
48:500-509. 626 
17. Cancer Genome Atlas Research Network. Electronic address wbe, Cancer Genome Atlas 627 
Research N: Comprehensive and Integrative Genomic Characterization of Hepatocellular 628 
Carcinoma. Cell 2017, 169:1327-1341 e1323. 629 
18. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W: Genome-wide analysis of noncoding 630 
regulatory mutations in cancer. Nat Genet 2014, 46:1160-1165. 631 
19. Ng CK, Piscuoglio S, Geyer FC, Burke KA, Pareja F, Eberle C, Lim R, Natrajan R, Riaz N, 632 
Mariani O, Norton L, Vincent-Salomon A, Wen YH, Weigelt B, Reis-Filho JS: The Landscape 633 
of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. Clin Cancer Res 2017. 634 
20. Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, Bidard FC, 635 
Berman S, Fusco N, Sakr RA, Eberle CA, De Mattos-Arruda L, Macedo GS, Akram M, 636 
Baslan T, Hicks JB, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS: The 637 
Genomic Landscape of Male Breast Cancers. Clin Cancer Res 2016, 22:4045-4056. 638 
  26 
21. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit 639 
DB, Olshen AB, Schultz N, Taylor BS: Identifying recurrent mutations in cancer reveals 640 
widespread lineage diversity and mutational specificity. Nat Biotechnol 2016, 34:155-163. 641 
22. Gao J, Chang MT, Johnsen HC, Gao SP, Sylvester BE, Sumer SO, Zhang H, Solit DB, 642 
Taylor BS, Schultz N, Sander C: 3D clusters of somatic mutations in cancer reveal 643 
numerous rare mutations as functional targets. Genome Med 2017, 9:4. 644 
23. Thorvaldsdottir H, Robinson JT, Mesirov JP: Integrative Genomics Viewer (IGV): high-645 
performance genomics data visualization and exploration. Brief Bioinform 2013, 14:178-192. 646 
24. Talevich E, Shain AH, Botton T, Bastian BC: CNVkit: Genome-Wide Copy Number Detection 647 
and Visualization from Targeted DNA Sequencing. PLoS Comput Biol 2016, 12:e1004873. 648 
25. Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, 649 
Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, 650 
Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnayan A, de Bono JS: Gene Copy Number 651 
Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: 652 
Analytic Validation and Clinical Qualification. Clin Cancer Res 2017, 23:6070-6077. 653 
26. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding 654 
L, Wilson RK: VarScan 2: somatic mutation and copy number alteration discovery in cancer 655 
by exome sequencing. Genome Res 2012, 22:568-576. 656 
27. Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary segmentation for the 657 
analysis of array-based DNA copy number data. Biostatistics 2004, 5:557-572. 658 
28. Li H, Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. 659 
Bioinformatics 2009, 25:1754-1760. 660 
  27 
29. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, 661 
Altshuler D, Gabriel S, Daly M, DePristo MA: The Genome Analysis Toolkit: a MapReduce 662 
framework for analyzing next-generation DNA sequencing data. Genome Res 2010, 663 
20:1297-1303. 664 
30. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, 665 
Meyerson M, Lander ES, Getz G: Sensitive detection of somatic point mutations in impure 666 
and heterogeneous cancer samples. Nat Biotechnol 2013, 31:213-219. 667 
31. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK: Strelka: accurate 668 
somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 669 
2012, 28:1811-1817. 670 
32. Shen R, Seshan VE: FACETS: allele-specific copy number and clonal heterogeneity 671 
analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 2016, 44:e131. 672 
33. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha 673 
R, Larsson E, Cerami E, Sander C, Schultz N: Integrative analysis of complex cancer 674 
genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6:pl1. 675 
34. Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, Tomlins SA, Reinig E, Beadling 676 
C, Andersen M, Corless CL: Assessing copy number alterations in targeted, amplicon-based 677 
next-generation sequencing data. J Mol Diagn 2015, 17:53-63. 678 
35. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, 679 
Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, 680 
Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, 681 
Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, 682 
Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, et al.: Mutational landscape of 683 
  28 
metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 684 
2017, 23:703-713. 685 
36. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White 686 
J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E, Zhao 687 
M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, 688 
Donahue A, Beltran H, Mosquera JM, Rubin MA, Dogan S, Hedvat CV, Berger MF, Pusztai 689 
L, Lechner M, Boshoff C, et al.: Development and validation of a clinical cancer genomic 690 
profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013, 31:1023-691 
1031. 692 
37. Pilati C, Letouze E, Nault JC, Imbeaud S, Boulai A, Calderaro J, Poussin K, Franconi A, 693 
Couchy G, Morcrette G, Mallet M, Taouji S, Balabaud C, Terris B, Canal F, Paradis V, 694 
Scoazec JY, de Muret A, Guettier C, Bioulac-Sage P, Chevet E, Calvo F, Zucman-Rossi J: 695 
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations 696 
and the mechanisms of malignant transformation. Cancer Cell 2014, 25:428-441. 697 
38. Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, 698 
Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, 699 
Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, 700 
Rebouissou S, Imbeaud S, Investigators G, Bioulac-Sage P, Letouze E, Zucman-Rossi J: 701 
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, 702 
and Malignant Transformation. Gastroenterology 2017, 152:880-894 e886. 703 
39. Goossens N, Sun X, Hoshida Y: Molecular classification of hepatocellular carcinoma: 704 
potential therapeutic implications. Hepat Oncol 2015, 2:371-379. 705 
40. Desert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, Bellaud P, Perret C, 706 
Clement B, Le Cao KA, Musso O: Human hepatocellular carcinomas with a periportal 707 
  29 
phenotype have the lowest potential for early recurrence after curative resection. Hepatology 708 
2017, 66:1502-1518. 709 
41. Kancherla V, Abdullazade S, Matter MS, Lanzafame M, Quagliata L, Roma G, Hoshida Y, 710 
Terracciano LM, Ng CKY, Piscuoglio S: Genomic Analysis Revealed New Oncogenic 711 
Signatures in TP53-Mutant Hepatocellular Carcinoma. Front Genet 2018, 9:2. 712 
42. Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, 713 
Quintavalle C, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, 714 
Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM, Piscuoglio S: Genetic 715 
profiling using plasma-derived cell-free DNA in therapy-naive hepatocellular carcinoma 716 
patients: a pilot study. Ann Oncol 2018. 717 
43. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, 718 
Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash 719 
FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, 720 
Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, 721 
Rathkopf D, Shoushtari AN, Shukla N, et al.: OncoKB: A Precision Oncology Knowledge 722 
Base. JCO Precis Oncol 2017, 2017. 723 
44. Cancer Genome Atlas Research: Comprehensive and Integrative Genomic Characterization 724 
of Hepatocellular Carcinoma. Cell 2017, 169:1327-1341 e1323. 725 
45. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, 726 
Daniels GA, Kurzrock R: Tumor Mutational Burden as an Independent Predictor of 727 
Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 2017, 16:2598-2608. 728 
46. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley 729 
KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, 730 
  30 
Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, 731 
Borad MJ, Cancer Genome Atlas N, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, 732 
Deshpande V, Mounajjed T, Foo WC, Torbenson MS, et al.: Integrative Genomic Analysis of 733 
Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 2017, 734 
19:2878-2880. 735 
 736 
  737 

0500
1000
1500
2000
2500
   F
res
h-f
roz
en
   N
on
-Tu
mo
r
M
ea
n 
A
m
pl
ic
on
 C
ov
er
ag
e
Fresh-frozen
Non-Tumor
Fresh-frozen
Tumor
FFPE
Non-Tumor
FFPE
Tumor
0.00
0.05
0.10
0.50
1.00
1.50
2.00
2.50
3.00
3.50
0.00 0.25 0.50 0.75 1.00M
ea
n 
N
or
m
al
iz
ed
 C
ov
er
ag
e
0.1
0.2
0.3
0.4
0.5
0.00
0.05
0.10
0.50
1.00
1.50
2.00
2.50
3.00
3.50
0.00 0.25 0.50 0.75 1.00M
ea
n 
N
or
m
al
iz
ed
 C
ov
er
ag
e
0.0
0.5
1.0
1.5
2.0
90%
92.5%
95%
97.5%
100%
1x 2x 10x 20x 30x
Pe
rc
en
ta
ge
 o
f t
ar
ge
t r
eg
io
ns Fresh-frozen
Non-Tumor
Fresh-frozen
Tumor
FFPE
Non-Tumor
FFPE
Tumor
Amplicon Length (bp)
Fr
eq
ue
nc
y
60 80 100 120 140 160 180 250
Figure 2
GC content - Fresh-frozen samples
GC content - FFPE samples
B
C
A
E
100
80
60
40
20
0
Sequencing depth
S.D.
S.D.
70%
80%
90%
100%
Fresh-frozen
U
ni
fo
rm
ity Type
Fresh-frozen
FFPE
D
FFPE
   F
res
h-f
roz
en
   T
um
or
 FF
PE
 Tu
mo
r
 FF
PE
   N
on
-Tu
mo
r


−3 −2 −1 0 1 2
−3
−2
−1
0
1
2
WES log2 ratio
H
C
C
 p
an
el
 (F
re
sh
-fr
oz
en
) l
og
2 
ra
tio
r=0.80
r2=0.64
−3 −2 −1 0 1 2
−3
−2
−1
0
1
2
WES log2 ratio
H
C
C
 p
an
el
 (F
FP
E
) l
og
2 
ra
tio
r=0.73
r2=0.54
<=
0.2
5
>0
.25
−0
.5
>0
.5−
1 >1
Absolute difference in log2 ratio
(Fresh-frozen samples)
Fr
eq
ue
nc
y
0
50
100
150
200
250
<=
0.2
5
>0
.25
−0
.5
>0
.5−
1 >1
Fr
eq
ue
nc
y
0
200
400
600
800
1000
1200
Absolute difference in log2 ratio
(FFPE samples)
Figure 5
A
B
  31 
FIGURE LEGENDS 738 
Figure 1: Design of the HCC sequencing panel and the study. (A) Frequencies of somatic 739 
mutations and copy number alterations in the genes included on the HCC panel according to 740 
previously published studies. (B) Outline of the study with the number of samples for each analysis 741 
performed. CNA: copy number alteration; FFPE: formalin-fixed paraffin-embedded; HCC: 742 
hepatocellular carcinoma; prom: promoter; WES: whole-exome sequencing. 743 
 744 
Figure 2: Coverage analyses and statistics of the HCC panel. (A) Distribution of the amplicon 745 
sizes on the HCC panel. (B) Violin plots of the mean amplicon coverage across fresh-frozen 746 
non-tumor, fresh-frozen tumor, FFPE non-tumor and FFPE tumor samples. (C) Percentages 747 
of target regions covered at various depths (1x, 2x, 10x, 20x and 30x) across fresh-frozen 748 
non-tumor, fresh-frozen tumor, FFPE non-tumor and FFPE tumor samples. (D) Coverage 749 
uniformity, defined as the percentage of target bases covered at >20% of the mean 750 
coverage, in fresh-frozen and FFPE non-tumor samples. (E) Scatter plot of GC content and 751 
mean normalized coverage for all amplicons in fresh-frozen and FFPE samples. Color of the 752 
dots indicates the standard deviation of mean normalized coverage within each group. 753 
FFPE: formalin-fixed paraffin-embedded; SD: standard deviation. 754 
 755 
Figure 3: Comparison of somatic mutations defined by whole-exome sequencing and HCC 756 
panel in fresh frozen tissues. (A) Number of coding and non-coding mutations per case identified 757 
in 10 fresh-frozen biopsies using the HCC panel. (B) Comparison of somatic coding and non-coding 758 
mutations found by WES and the HCC panel in the fresh-frozen samples. Heatmaps indicate the 759 
variant allele fractions of the somatic mutations (blue, see color key) or their absence (grey) in the 8 760 
cases in which at least one somatic mutation was identified. Mutation types are indicated as colored 761 
dots according to the color key. Mutations that were not called by mutation caller but were 762 
supported by at least 1 sequencing read are indicated by an asterisk. HCC: hepatocellular 763 
carcinoma; WES: whole-exome sequencing. 764 
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 765 
Figure 4: Comparison of somatic mutations defined by whole-exome sequencing and HCC 766 
panel in FFPE tissue. Barplot illustrates the number of somatic coding and non-coding mutations 767 
found in 36 FFPE tumor biopsies using the HCC panel. In the main panel, each row represents a 768 
gene on the HCC panel and each column represents a sample. The mutations identified by WES in 769 
the fresh-frozen biopsies and those defined by sequencing the corresponding FFPE samples using 770 
the HCC panel are placed next to each other. Mutation types are color coded according to the color 771 
key. The presence of multiple mutations in the same gene is illustrated by an asterisk. Non-coding 772 
regions below the dotted line were not covered by WES. FFPE: formalin-fixed paraffin-embedded; 773 
WES: whole-exome sequencing. 774 
 775 
Figure 5: Copy number profiling using the HCC panel. (A) Scatter plots illustrate the copy 776 
number log2 ratio of WES and HCC panel sequencing of the fresh-frozen (left) and the FFPE (right) 777 
tumor samples. (B) Barplots illustrate the number of genes with concordant (dark grey) or 778 
discordant (light grey) copy number states, binned by the absolute difference in copy number log2 779 
ratio between WES and HCC panel sequencing of the fresh-frozen (left) and FFPE (right) samples. 780 
FFPE: formalin-fixed paraffin-embedded; HCC: hepatocellular carcinoma; WES: whole-exome 781 
sequencing. 782 
